Dario Marchetti, Ph.D. is a tumor and molecular biologist. Dr. Marchetti formerly served as the “Jack L. Titus” endowed Professor at Baylor College of Medicine, and currently holds a visiting Professor appointment in the Department of Molecular & Cellular Biology at Baylor College of Medicine.
Dr. Marchetti is an internationally recognized authority in the field of circulating tumor cells (CTCs). CTCs and CTC-based biomarker signatures can be clinically useful tools for monitoring cancer progression in the patient in "real-time;" and for combating cancer metastasis for improved patient outcome as prime examples of precision medicine. With keen insights into the biology of brain metastasis, Dr. Marchetti pioneered models by discovering molecular determinants underlying brain metastasis and biomarker properties of brain metastasis-associated and brain-colonizing CTCs. As a consummate scientist, Dr. Marchetti’s bibliography include 180 publications of which 80 are in peer-reviewed journals in the fields of neuroscience and oncology. He has received numerous awards and secured uninterrupted funding since 1990 by receiving grants from federal, state, institutional and private agencies. He is a reviewer for the most prominent journals in cancer research and sits on editorial boards of “Cancer Microenvironment, “Vascular Cell”, "Clinical & Experimental Pathology", "International Journal of Oncology", “Cancer Letters”, “Journal of Cellular Biochemistry”, “Discovery/Discovery Reports” (a journal from Harvard Medical School) and "Cancer Metastasis Reviews" among others. Dr. Marchetti also acts as Guest Editor on a special tome on brain metastasis by the International Journal of Molecular Sciences (Basel, Switzerland) and an invited Editor on a special volum on CTCs by Frontiers Research Topic Oncology (Lausanne Switzerland). Further, he serves as standing member on grant reviewing panels of the National Institutes of Health of USA and Italy, the Department of Defense of the US, and is frequently invited as grant reviewer and consultant for multiple national and international agencies and pharma companies devoted to oncology research.
Dr. Marchetti graduated from the University of Pavia, Italy in 1979. He worked as postdoctoral fellow at the University of Illinois, Chicago (1980-1982) and the University of Texas Medical Branch – Galveston (Texas) (1984-1986). He then became a research scientist at the University of Texas Health Science Center-Houston (1986-1991), Research Associate and later Instructor at MD Anderson Cancer Center (1992-1999), Assistant Professor at UT-Houston (1999-2001), Associate Professor and later Professor (with tenure) at LSU-Baton Rouge, Louisiana (2002-2007), Professor with tenure at Baylor College of Medicine (2008-2015) prior to joining the Faculty of Houston Methodist Hospital (September 2015).
Scientific focus of Dr. Marchetti’s laboratory is to investigate the biology, properties and clinical utilities of Circulating Tumor Cells (CTCs) directly isolated from cancer patients and “seeds” of fatal metastatic disease. Metastasis, the major cause of cancer patients’ mortality (>90% of cancer deaths). CTCs are proving to be potent prognostic and diagnostic tools for noninvasive "real-time" assessment of cancer progression (the concept of "liquid biopsy”). Evaluation of CTCs and CTC biomarkers can enable a more sensitive monitoring of treatment efficacy, thus guiding drug selection in adjuvant settings where no such tools exist today. However, current technologies prevent researchers from identifying the majority of the CTCs from cancer patients that metastasize within the body, e.g., to brain. Brain metastasis represents an urgent clinical problem which is increasing in frequency with dismal patient survival rates. Brain metastasis are estimated to become the No. 1 cancer killer and the number of patient cases with brain metastasis already outnumber breast cancer cases in the U.S. alone.
Dr. Marchetti and team are working to develop a vigorous biomarker research program with Houston Methodist Hospital faculty across numerous disciplines with a primary focus on breast cancer brain metastasis. One of his key priorities is to better understand why breast cancer reoccurs and how to decipher the molecular heterogeneity of CTC phenotypes which are responsible for seeding/reseeding metastasis leading to patients’ death.